editorial Archives | Page 2 of 3

Oncotarget News

The Role of Artificial Intelligence in Advancing Intratumoral Immunotherapy

September 19, 2024

We explore how integrating these technologies could revolutionize personalized oncology.”BUFFALO, NY- September 19, 2024 – A new editorial was published in Oncotarget's Volume 15 on September 17, 2024, entitled, “The... read more

Oncotarget

Targeting CD47/SIRPα “Do Not Eat Me” Axis: Advances and Challenges in Cancer Therapy

September 11, 2024

Numerous phagocytosis checkpoints and ‘do not eat me’ signals (i.e., CD47, CD24, MHC-I, PD-L1, STC1, and GD2) have recently been recognized as potential therapeutic targets.”BUFFALO, NY- September 11,... read more

Oncotarget

Next-Gen Vaccines Offer New Hope Against Glioblastoma

September 9, 2024

Vaccines have been considered a promising approach for GBM for many years.”BUFFALO, NY- September 9, 2024 – A new editorial was published in Oncotarget's Volume 15 on August 5, 2024,... read more

Oncotarget

Generative AI in Cancer Imaging: Revolutionizing Detection & Diagnosis

September 6, 2024

This editorial explores its impact on expanding datasets, improving image quality, and enabling predictive oncology.”BUFFALO, NY- September 6, 2024 – A new editorial was published in Oncotarget's Volume 15 on... read more

Oncotarget

Graph Filtration Learning Reveals New Dimensions in Hepatocellular Carcinoma Imaging

August 30, 2024

In medical imaging, our understanding of hepatocellular carcinoma (HCC) has long been constrained by the limitations of pixel-based analysis.”BUFFALO, NY- August 30, 2024 – A new editorial was published in... read more

Oncotarget

Artificial Intelligence: Revolutionizing Precision Oncology

August 27, 2024

Properly leveraged AI-based techniques could herald a new era of precision medicine guided by non-invasive, imaging-based disease evaluation."BUFFALO, NY- August 27, 2024 – A new editorial was published in Oncotarget's... read more

Oncotarget

Genotype Matters: Tailored Screening for Germline CHEK2 Variants

August 26, 2024

In our study, we postulated that these differences were driven by three common low-risk (LR) missense variants: p.I157T, p.S428F, and p.T476M, all of which have a BC... read more

Oncotarget

Disrupting NKG2A:HLA-E Interactions for Enhanced Anti-Cancer Immunity

August 21, 2024

there is strong preclinical evidence that disruption of NKG2A interactions with HLA-E can stimulate both NK cell and cytotoxic T cell effector functions against cancer.”BUFFALO, NY- August 21, 2024 –... read more

Oncotarget

Dealing with Runaway Metastatic Disease

August 7, 2024

Metastatic disease remains a major issue in daily practice in oncology because the outcome is still often fatal.”BUFFALO, NY - August 7, 2024 – A new editorial paper was published in... read more

Oncotarget

One More Step Toward Treatment of PARP Inhibitor-resistant Ovarian Cancers

January 10, 2024

This initiative is geared towards identifying additional biomarkers that can aid in selecting the most appropriate treatments for ovarian cancer.”BUFFALO, NY- January 10, 2024 – A new editorial paper was... read more